Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$33.49

-1.61 (-4.59%)

11:45
12/02/16
12/02
11:45
12/02/16
11:45

The Medicines Co. management to meet with JPMorgan

Group luncheon to be held in New York on December 2 hosted by JPMorgan.

MDCO The Medicines Co.
$33.49

-1.61 (-4.59%)

11/16/16
NEED
11/16/16
NO CHANGE
Target $98
NEED
Buy
Alnylam price target lowered to $98 from $137 at Needham
Needham analyst Alan Carr lowered his price target for Alnylam (ALNY) to $98 from $137 after the company announced that collaborator Sanofi (SNY) exercised its option to co-develop and co-commercialize fitusiran, with the analyst adjusting his models to reflect Sanofi taking greater share of revenue. He also notes that Alnylam's collaborator The Medicines Co. (MDCO) announced positive Phase 2 PCSK9 results. Carr reiterates a Buy rating on Alnylam's shares.
11/16/16
RBCM
11/16/16
NO CHANGE
RBCM
The Medicines Co. price target raised to $52 from $45 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on The Medicines Company after it reported Phase 2 data on its inclisiran drug that he views positively. The analyst says that the drug has differentiated efficacy and safety in LDL-C reduction. He thinks that safety questions created an overhang on the stock, but he still believes that the shares should have risen. The analyst believes that additional data due to be released by the company at the end of the year will be positive. He keeps an Outperform rating on the shares.
11/16/16
LEER
11/16/16
NO CHANGE
Target $57
LEER
Outperform
The Medicines Co. price target raised to $57 from $50 at Leerink
Leerink analyst Joseph Schwartz raised his price target for The Medicines Co. to $57 from $50 following the Phase 2 ORION-1 data presentation at the American Heart Association meeting, and after the company provided an extensive walk-through of the safety findings in addition to encouraging efficacy and durability data. The analyst also raised his probability of success for inclisiran to 60% from 50%. He reiterates an Outperform rating on the shares.
11/15/16
PIPR
11/15/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using today's selloff in shares of Alnylam Pharmaceuticals (ALNY) as a buying opportunity. Alnylam's partner The Medicine's Company (MDCO) presented today positive interim safety and efficacy data from the Phase II ORION-1 study of inclisiran, but the stock is weak today on one fatal heart attack in the 500mg inclisiran arm unrelated to study drug, Tenthoff tells investors in a research note. The analyst was impressed by the drug's efficacy and reiterates an Overweight rating on Alnylam with a $106 price target. The stock is down 3% to $48.36 in afternoon trading.

TODAY'S FREE FLY STORIES

KMB

Kimberly-Clark

$113.44

-2.11 (-1.83%)

07:30
10/23/17
10/23
07:30
10/23/17
07:30
Earnings
Kimberly-Clark reports Q3 EPS $1.60, consensus $1.54 »

Reports Q3 revenue $4.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WFT

Weatherford

$3.54

-0.16 (-4.32%)

, BSX

Boston Scientific

$29.69

0.12 (0.41%)

07:30
10/23/17
10/23
07:30
10/23/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

WFT

Weatherford

$3.54

-0.16 (-4.32%)

BSX

Boston Scientific

$29.69

0.12 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 01

    Nov

  • 06

    Nov

VFC

VF Corp.

$66.38

1.03 (1.58%)

07:29
10/23/17
10/23
07:29
10/23/17
07:29
Technical Analysis
Technical View: VF Corp. hits fresh 52-week high after earnings beat »

The stock was last at $69…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HAS

Hasbro

$98.19

1.52 (1.57%)

07:28
10/23/17
10/23
07:28
10/23/17
07:28
Earnings
Hasbro sees Q4 revenue up 4%-7%, consensus $1.82B »

"The quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SALT

Scorpio Bulkers

$8.20

0.45 (5.81%)

07:28
10/23/17
10/23
07:28
10/23/17
07:28
Earnings
Scorpio Bulkers reports Q3 GAAP EPS (15c), consensus (13c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALGN

Align Technology

$200.88

4.03 (2.05%)

07:28
10/23/17
10/23
07:28
10/23/17
07:28
Recommendations
Align Technology analyst commentary  »

Align Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 06

    Nov

FL

Foot Locker

$31.28

0.29 (0.94%)

07:27
10/23/17
10/23
07:27
10/23/17
07:27
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:27
10/23/17
10/23
07:27
10/23/17
07:27
Recommendations
DBV Technologies analyst commentary  »

Barclays cuts DBV target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:27
10/23/17
10/23
07:27
10/23/17
07:27
Hot Stocks
Breaking Hot Stocks news story on Deltic Timber »

Deltic Timber jumps 7% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

ROKU

Roku

$21.87

-0.16 (-0.73%)

07:25
10/23/17
10/23
07:25
10/23/17
07:25
Initiation
Roku initiated  »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

, CLVS

Clovis

$77.50

0.73 (0.95%)

07:24
10/23/17
10/23
07:24
10/23/17
07:24
Initiation
Tesaro, Clovis initiated  »

Tesaro initiated with an…

TSRO

Tesaro

$116.40

0.89 (0.77%)

CLVS

Clovis

$77.50

0.73 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

NCNA

NuCana

$14.08

-0.3 (-2.09%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Initiation
NuCana initiated  »

NuCana initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:23
10/23/17
10/23
07:23
10/23/17
07:23
General news
Futures higher ahead of buy week of earnings »

Stock futures are…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Aimmune, DBV Technologies analyst commentary  »

Aimmune price target…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FL

Foot Locker

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.18

1.73 (1.85%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JPM

JPMorgan

$99.51

1.4 (1.43%)

07:22
10/23/17
10/23
07:22
10/23/17
07:22
Periodicals
JPMorgan, Mosaic Smart Data partner to boost fixed-income trading, Reuters says »

JPMorgan has teamed up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CLVS

Clovis

$77.50

0.73 (0.95%)

07:21
10/23/17
10/23
07:21
10/23/17
07:21
Initiation
Clovis initiated  »

Clovis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BIIB

Biogen

$338.10

-4.32 (-1.26%)

, ESALY

Eisai

$53.38

-0.25 (-0.47%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Hot Stocks
Biogen, Eisai expand existing collaboration agreement »

Eisai Co., Ltd. (ESALY)…

BIIB

Biogen

$338.10

-4.32 (-1.26%)

ESALY

Eisai

$53.38

-0.25 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

NITE

Nightstar Therapeutics

$19.00

-0.1 (-0.52%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Initiation
Nightstar Therapeutics initiated  »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Earnings
Potlatch reports Q3 EPS ex-items 94c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Hot Stocks
Potlatch raises dividend to 40c per share from 37.5c per share »

Potlatch announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAIC

SAIC

$70.88

1.04 (1.49%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Upgrade
SAIC rating change  »

SAIC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GGB

Gerdau

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Gerdau initiated  »

Gerdau resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Vale initiated  »

Vale resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.